Supplemental Table 1.
The clinical data of 94 ruptured HCC patients who received different initial treatments
| Variables | Conservative treatment (n=21) | Surgical hemostasis (n=14) | TAE (n=59) | P |
|---|---|---|---|---|
| Gender (male/female) | 16/5 | 12/2 | 53/6 | 0.29 |
| Age (years), mean±SD | 52.7±14.5 | 50.3±11.9 | 58.3±13.0 | 0.072 |
| HBsAg (positive/negative) | 19/2 | 11/3 | 48/11 | 0.62 |
| Shock on admission (yes/no) | 7/14 | 6/8 | 12/47 | 0.16 |
| Liver cirrhosis (yes/no) | 15/6 | 12/2 | 38/21 | 0.33 |
| Ruptured tumor location (RL/LL) | 17/4 | 7/7 | 43/16 | 0.13 |
| Tumor number (single/multiple) | 7/14 | 7/7 | 31/28 | 0.31 |
| Tumor size (cm), mean±SD | 9.0±3.4 | 9.0±3.5 | 9.1±3.3 | 0.96 |
| Modified LCSGJ stage (II/III/IV) | 4/5/12 | 6/7/1 | 29/20/10 | <0.001 |
| AFP (<400/≥400ng/mL) | 4/17 | 6/8 | 29/30 | 0.055 |
| Hemoglobin (g/L), mean±SD | 93.8±23.3 | 113.4±24.0 | 107.9±21.3 | 0.008 |
| ALT (U/L), mean±SD | 80.8±74.6 | 59.0±26.0 | 70.7±95.0 | 0.76 |
| Child-Pugh class (A/B/C) | 4/10/17 | 11/3/0 | 30/24/5 | 0.002 |
| 30-day mortality (yes/no) | 14/7 | 2/12 | 9/50 | <0.001 |
HCC, hepatocellular carcinoma; TAE, transarterial embolization; HBsAg, hepatitis B surface antigen; RL, right lobe; LL, left lobe; LCSGJ, the Liver Cancer Study Group of Japan; AFP, alpha-fetoprotein; ALT, alanine aminotransferase.